financetom
Business
financetom
/
Business
/
Franklin BSP Realty Q3 net income drops 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Franklin BSP Realty Q3 net income drops 
Oct 29, 2025 2:25 PM

Overview

* Franklin BSP Realty Trust ( FBRT ) Q3 net income falls to $17.6 mln from $24.4 mln in Q2

* Diluted EPS for Q3 drops to $0.12 from $0.19 in Q2 2025

* Company completed $1.1 bln commercial real estate mortgage securitization

Outlook

* Company did not provide specific guidance for future quarters or the full year in the statement

Result Drivers

* NEW LOAN COMMITMENTS - Closed $304.2 mln of new loan commitments at a weighted average spread of 511 basis points

* ACQUISITION IMPACT - Acquired NewPoint Holdings for $425 mln, integration progressing well, per President Michael Comparato

* SECURITIZATION TRANSACTION - Closed $1.1 bln commercial real estate mortgage securitization transaction

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $29.42

Revenue mln

Q3 EPS $0.12

Q3 Net $17.61

Income mln

Q3 Net $29.67

Interest mln

Income

Q3 Loan $569,000

Loss

Provisio

n

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialized reits peer group is "hold."

* Wall Street's median 12-month price target for Franklin BSP Realty Trust Inc ( FBRT ) is $14.25, about 25.2% above its October 29 closing price of $10.66

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ford Could Become 'Compelling' Story in 2026 if EV Losses Improve, RBC Says
Ford Could Become 'Compelling' Story in 2026 if EV Losses Improve, RBC Says
Oct 24, 2025
02:05 PM EDT, 10/24/2025 (MT Newswires) -- Ford's (F) third-quarter results were strong, though the automaker must arrest continued losses in its electric-vehicle business to become a compelling story in 2026, RBC Capital Markets said in a note e-mailed Friday. Late Thursday, Ford reported third-quarter adjusted earnings of $0.45 a share, down from $0.49 a year earlier, while revenue rose...
Vivakor Prices $3.5 Million Direct Securities Offering
Vivakor Prices $3.5 Million Direct Securities Offering
Oct 24, 2025
02:05 PM EDT, 10/24/2025 (MT Newswires) -- Vivakor ( VIVK ) priced a direct offering of common stock and prefunded warrants to a single institutional investor, aiming to raise $3.5 million. The offering, expected to close around Monday, includes 10.9 million shares and 5 million warrants, the company said Friday in a statement. Price: 0.31, Change: +0.05, Percent Change: +19.72...
Silver Bullet Mines Ships First Commercial Quantity of Gold And Silver Concentrate
Silver Bullet Mines Ships First Commercial Quantity of Gold And Silver Concentrate
Oct 24, 2025
01:57 PM EDT, 10/24/2025 (MT Newswires) -- Silver Bullet Mines ( SBMCF ) on Friday said it shipped its first commercial quantity of gold and silver concentrate from the KT Mine in Arizona and confirms no tariff issues are expected with the shipment. The company, which expects to make concentrate shipments regularly, also plans to increase the quantity and frequency...
Syndax's Revumenib Gets FDA Approval for Acute Myeloid Leukemia
Syndax's Revumenib Gets FDA Approval for Acute Myeloid Leukemia
Oct 24, 2025
01:51 PM EDT, 10/24/2025 (MT Newswires) -- Syndax's (SNDX) revumenib was approved by the US Food and Drug Administration as a treatment for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, the regulator said Friday. The drug was approved for use in adults and children at least one year old who have no satisfactory alternative treatment options,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved